^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD8701

    i
    Other names: AZD8701, ION-AZ7, FOXP3rx, AZD-8701, AZD 8701, ION AZ7, Gen 2.5 cEt-modified ASO, IONIS-AZ7-2.5Rx, ION736
    Associations

    News

    Trials
    Company:
    AstraZeneca, Ionis
    Drug class:
    FOXP3 inhibitor
    Associations

    News

    Trials
    1year
    AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: Phase I trial in Patients with Advanced Solid Tumors. (PubMed, Clin Cancer Res)
    This study demonstrates the clinical feasibility of ASO therapy, with generally manageable AEs, FOXP3 knockdown, and ASO delivery to the tumor.
    P1 data • Journal • PD(L)-1 Biomarker
    |
    FOXP3 (Forkhead Box P3)
    |
    Imfinzi (durvalumab) • AZD8701
    over1year
    First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=60, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Oct 2024 | Trial primary completion date: Jan 2025 --> Oct 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Imfinzi (durvalumab) • AZD8701
    almost2years
    First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Imfinzi (durvalumab) • AZD8701
    over2years
    First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, AstraZeneca | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Imfinzi (durvalumab) • AZD8701
    almost3years
    Immunotherapies that repolarize macrophages and CD4 T cells enhance the effect of chemotherapy in high-grade serous ovarian cancer (AACR 2023)
    Combinations of chemotherapy with anti-stabilin1 antibody and/or FOXP3 inhibitor (AZD8701), FOXP3i, significantly increased median survival of mice with established peritoneal disease...There was significant reduction in FOXP3 positive cells and significant increase of Tbet positive cells in FOXP3i treated murine tumors suggesting repolarization of naive T cells in the tumor microenvironment towards a more anti-tumor T helper phenotype. As there are early phase clinical trials of FOXP3 inhibitor and anti-stabilin1 (Clever-1) antibody in patients with advanced cancer, these results suggest ways of improving response to chemotherapy not only in HGSOC but in other cancers that are treated by NACT.
    Late-breaking abstract
    |
    CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    AZD8701
    3years
    First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=153 --> 61 | Trial completion date: Jan 2024 --> May 2023 | Trial primary completion date: Jan 2024 --> May 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Imfinzi (durvalumab) • AZD8701
    almost4years
    Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors. (ASCO 2022)
    This is a Phase I multicenter study of AZD8701 alone or in combination with durvalumab in participants with selected advanced solid tumors. Secondary endpoints include, disease control rate, duration of response, progression free survival and overall survival, pharmacokinetics and pharmacodynamics (including changes in Foxp3 mRNA in paired tumor samples). The trial is currently recruiting.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Imfinzi (durvalumab) • AZD8701
    almost4years
    First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=153, Recruiting, AstraZeneca | Trial completion date: Sep 2023 --> Jan 2024 | Trial primary completion date: Sep 2023 --> Jan 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Imfinzi (durvalumab) • AZD8701
    over5years
    First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=110, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy • PD(L)-1 Biomarker
    |
    FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Imfinzi (durvalumab) • AZD8701
    over5years
    First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=123, Not yet recruiting, AstraZeneca
    Clinical • New P1 trial • Combination therapy • PD(L)-1 Biomarker
    |
    FOXP3 (Forkhead Box P3)
    |
    FOXP3 expression
    |
    Imfinzi (durvalumab) • AZD8701